Skip to main content

TCG Crossover — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$14.3B
Total invested
$176.4M
Avg. check
15
Industries
Biotechnology 24Health Care 15Therapeutics 12Pharmaceutical 11Medical 11Biopharma 5+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 81
Athira Pharma
December 2025

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

Biotechnology · Seattle$90.0M Post-IPO Equity
Immunovant
December 2025

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Biopharma · New York$550.0M Post-IPO Equity
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post-IPO Debt
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post-IPO Equity
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Plexium
August 2025

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Biotechnology · San Diego$60.1M Series C
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoVenture - Series Unknown
Aviceda Therapeutics
January 2025

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

Biotechnology · Cambridge$207.5M Series C
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
Vicebio
September 2024

Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.

Biotechnology · London$100.0M Series B
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
Entrada Therapeutics
June 2024

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Biotechnology · Boston$100.0M Post-IPO Equity
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post-IPO Equity
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Alkeus Pharmaceuticals
June 2023

Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Biotechnology · Cambridge$150.0M Series B
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
VectivBio
October 2022

VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.

Biotechnology · Basel$125.0M Post-IPO Equity
Allakos
September 2022

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

Biopharma · Redwood City$150.0M Post-IPO Equity
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Versanis Bio
August 2021

Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.

Biotechnology · Oakland$70.0M Series A
LB Pharmaceuticals
February 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$100.0M Post Ipo Equity

Where TCG Crossover invests

Biotechnology24
Health Care15
Therapeutics12
Pharmaceutical11
Medical11
Biopharma5

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?▸

TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?▸

TCG Crossover's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 15 different industry categories.

What is TCG Crossover's largest investment?▸

Among tracked funding rounds, Immunovant received $550.0M in a Post-IPO Equity round. TCG Crossover's total known invested capital is $14.3B.

What is the average investment size for TCG Crossover?▸

TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.

What are TCG Crossover's most recent investments?▸

Recent TCG Crossover portfolio additions include Athira Pharma, Immunovant, Cogent Biosciences, Rapt Therapeutics, Affinia Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →